GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pressure BioSciences Inc (OTCPK:PBIO) » Definitions » Debt-to-Equity

PBIO (Pressure BioSciences) Debt-to-Equity : -0.71 (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Pressure BioSciences Debt-to-Equity?

Pressure BioSciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $26.56 Mil. Pressure BioSciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.54 Mil. Pressure BioSciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-38.13 Mil. Pressure BioSciences's debt to equity for the quarter that ended in Mar. 2024 was -0.71.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Pressure BioSciences's Debt-to-Equity or its related term are showing as below:

PBIO' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.92   Med: -0.65   Max: -0.05
Current: -0.71

During the past 13 years, the highest Debt-to-Equity Ratio of Pressure BioSciences was -0.05. The lowest was -0.92. And the median was -0.65.

PBIO's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.22 vs PBIO: -0.71

Pressure BioSciences Debt-to-Equity Historical Data

The historical data trend for Pressure BioSciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pressure BioSciences Debt-to-Equity Chart

Pressure BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.66 -0.57 -0.66 -0.63 -0.70

Pressure BioSciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.61 -0.77 -0.74 -0.70 -0.71

Competitive Comparison of Pressure BioSciences's Debt-to-Equity

For the Medical Devices subindustry, Pressure BioSciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pressure BioSciences's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pressure BioSciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Pressure BioSciences's Debt-to-Equity falls into.



Pressure BioSciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Pressure BioSciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Pressure BioSciences's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pressure BioSciences  (OTCPK:PBIO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Pressure BioSciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Pressure BioSciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Pressure BioSciences Business Description

Traded in Other Exchanges
N/A
Address
14 Norfolk Avenue, South Easton, MA, USA, 02375
Pressure BioSciences Inc is engaged in the healthcare division. The firm is a leader in the development & sale of enabling, pressure-based platform solutions for the world-wide life sciences industry. The company has developed and patented a technology platform that can control the sample preparation process. This process, called pressure cycling technology (PCT), uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels. The company is also the distributor of the Constant Systems (CS) cell disruption equipment, parts, and consumables. Its products include Barocyclers, External Pressure Calibration Device Kits, MicroTubes, HUB High-Pressure Generators, and Accessories.
Executives
Daniel Joseph Shea officer: Senior Vice President & CFO 2 MINUTEMAN ROAD, MEDFIELD MA 02052
Bradford Addison Young officer: Chief Commercial Officer 513 LITTLE JOHN HILL, ANNAPOLIS MD 21405
Richard T Schumacher director, officer: Chief Executive Officer 375 WEST STREET, WEST BRIDGEWATER MA 02379
Nathan Lawrence other: VP Sales and Marketing 321 MANLEY STREET, WEST BRIDGEWATER MA 02379
Richard Thomley officer: Chief Financial Officer C/O PRESSURE BIOSCIENCES, INC., 14 NORFOLK AVE., SOUTH EASTON MA 02375
Kevin Pollack director 150 RAINVILLE ROAD, TARPON SPRINGS FL 34689
Michael S Urdea director 100 BUNCE MEADOWS DRIVE, ALAMO CA 94507
Alexander V Lazarev officer: VP of REsearch and Development 18 WINCHESTER DRIVE, LEXINGTON MA 02420
Edmund Y Ting officer: Senior VP of Engineering 23642 123RD PLACE SOUTHEAST, KENT WA 48031
Vito J Mangiardi director 12 POINT GALLINAS ROAD, SAN RAFAEL CA 94903
Jeffrey N Peterson director 1031 SHORELINE DRIVE, SAN MATEO CA 94404
Mir Conrad F officer: CFO 19 BRIER LANE, CLIFTON NJ 07012
Clayton A Struve 10 percent owner 175 W JACKSON BLVD, SUITE 440, CHICAGO IL 60604
Css Llc/il other: (a) 175 WEST JACKSON BLVD, SUITE 440, CHICAGO IL 60604
R Wayne Fritzsche director 835 GREENS PARKWAY, SUITE 150, HOUSTON TX 77067